Loading organizations...
§ Private Profile · London, United Kingdom
Digital health platform and app for Hashimoto's and hypothyroidism patients, offering personalized plans and tracking.
Hashiona, a London, England-based digital health platform and app, empowers individuals with Hashimoto's thyroiditis and hypothyroidism to achieve remission through lifestyle changes. Founded in 2020 by Eva Galant (CEO), Konrad Koniarski (CTO), and Daniel Świątkowski (COO), the company offers comprehensive support. Its subscription-based services include personalized nutrition plans, detailed symptom tracking, educational resources, blood test analysis, and direct clinician chats. In 2023, Hashiona successfully secured €450,000 in pre-seed funding from notable investors like COBIN Angels, Draper University, KAYA, and Calm/Storm. This crucial investment fuels its strategic expansion into English and German-speaking markets, targeting patients globally within the vital femtech and digital health sectors. Hashiona's virtual clinic and app provide data-driven insights and professional guidance, enabling users to proactively manage their condition and improve their well-being.
Hashiona has raised $540K across 1 funding round.
Hashiona has raised $540K in total across 1 funding round.
Hashiona has raised $540K across 1 funding round. Most recently, it raised $540K Seed in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2021 | $540K Seed | — | Bloomberg Beta, Draper Associates, Freestyle Capital, K9 Ventures, Reach Capital, The House Fund, Daniel Świątkowski, Pawel Wozniak, Slawek Szymankiewicz, Michael Strock, Dfri, Andrew Tang, Kaya | Announced |
Hashiona has raised $540K in total across 1 funding round.
Hashiona's investors include Bloomberg Beta, Draper Associates, Freestyle Capital, K9 Ventures, Reach Capital, The House Fund, Daniel Świątkowski, Pawel Wozniak, Slawek Szymankiewicz, Michael Strock, DFRI, Andrew Tang.
Hashiona is a digital health platform specializing in Hashimoto's Thyroiditis management, offering personalized nutrition plans, symptom tracking, medication and hydration monitoring, educational resources, and data analytics to improve users' quality of life.[1][2][5] It serves individuals worldwide with the autoimmune condition, addressing challenges like inflammation through data-driven diets, virtual clinic support, and expert-backed tools, while aiming to become the global leader in patient monitoring for this disease.[1][2][3] Founded in 2020 at the incubator/accelerator stage, it has raised $450K (with some sources noting ~$0.30M-$0.84M), achieved over 25K beta testers, and gained media features in outlets like Wired, Elle, and MIT Sloan Review.[1][2][3]
Hashiona was founded in 2020 by Eva Galent, who launched the platform from London, England (with operations noted in Wroclaw, Poland), driven by the need for specialized management of Hashimoto's Thyroiditis and hypothyroidism.[1][4] Galent emphasized testing thyroid biomarkers like antibodies to prove dietary interventions reduce inflammation, combining a holistic approach with tech for better patient outcomes.[1] Early traction came via partnerships like Medichecks' Plasma platform for remote blood testing, enabling reliable diet monitoring, while development involved Flutter app creation by a Polish team, leading to quick launches on Google Play and App Store with dynamic features like backend-driven infographics and subscriptions.[1][2]
Hashiona rides the digital health boom in personalized chronic disease management, targeting the underserved Hashimoto's market amid rising autoimmune diagnoses and demand for remote, data-driven care post-COVID.[1][2] Timing aligns with telehealth growth, biomarker tech advancements (e.g., partnerships like Medichecks), and consumer shift to nutrition-focused wellness apps, fueled by market forces like aging populations and inflammation research.[1] It influences the ecosystem by aggregating patients for global leadership in monitoring, educating users, and enabling diagnostics-as-a-service, potentially lowering healthcare burdens via preventive diets and setting standards for niche condition platforms.[1][2][3]
Hashiona is poised for expansion through user growth beyond 25K testers, deeper biomarker integrations, and potential scaling to full virtual clinic services amid rising hypothyroidism awareness.[1][2][3] Trends like AI-driven personalization, subscription health models, and global telehealth regulations will shape its path, amplifying impact via partnerships and media momentum. Its influence may evolve from niche tracker to ecosystem leader, empowering Hashimoto's patients with lifelong tools—reinforcing its mission to transform lives through accessible, evidence-based care.[1][5]